Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript
Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.
How this was made
The 30-second read
Why it matters
The key tradable elements are the reaffirmed full-year adjusted EBITDA range and management’s explicit expectation that RCM collections tailwind will dissipate in 2H 2026, potentially affecting pricing growth despite guidance.
Market read
A guidance-reaffirming earnings call with a specific forward-looking risk to pricing growth (RCM collections) and notable working-capital and cash changes.
What to watch
Operating cash flow fell and cash declined materially from year-end, so traders may watch whether working-capital dynamics (DSO, receivables) continue to pressure liquidity even if EBITDA holds.
Background
Pediatrix Medical Group’s Q2 2026 earnings call covered revenue drivers, margin metrics, cash flow, and 2026 guidance, including telehybrid care strategy.
Ticker impact
Pediatrix reported Q2 2026 revenue of $487.8M and raised/maintained full-year 2026 adjusted EBITDA guidance at $280M to $300M.
Near-term sentiment likely hinges on whether investors focus on reaffirmed EBITDA guidance versus the warned slowdown in RCM-driven pricing growth.
The call includes multiple quantified datapoints (revenue, adjusted EPS, cash/DSO, guidance) plus a specific risk statement about RCM collections weakening in 2H 2026, which can change forward expectations even with guidance reaffirmed.
Market effects
Reinforces that specialty healthcare operators’ earnings sensitivity is heavily tied to revenue cycle management collections and payer mix shifts.
No specific regional impact disclosed beyond national footprint and telemedicine expansion.
Limited, as the disclosure is company-specific and US healthcare delivery focused.
Counterpoint
Investors may underweight the volume decline because pricing drivers (RCM collections, payer mix, acuity) were described as concentrated and management reaffirmed full-year EBITDA guidance.
Key entities
- companyPediatrix Medical Group, Inc.
Reported Q2 2026 results and reaffirmed full-year 2026 adjusted EBITDA guidance; discussed RCM collections outlook and telehybrid expansion.
- executiveMark Ordan
CEO who discussed telemedicine combined with physical visits and expectations for volume trends.
- executiveKasandra Rossi
CFO who provided guidance details and flagged RCM collections tailwind dissipation in 2H 2026.
